Establishment of three human induced pluripotent stem cell lines from a type 1 diabetic family harboring sequence variants associated with autoimmunity

Chu, Edward; Lin, Chia-Hung; Cho, Candy Hsin-Hua; Cheng, I-Fen; Kuo, Tzu-Chien; Chen, Ruei-Ying; Liao, Chia-Nan; Cheng, Jen-Chien; Tsai, Jason; Wang, Po-Chuan; Chang, Shing‐Jyh; Shen, Chia-Ning

doi:10.1016/j.scr.2020.102029

Cited by 1 publication

(1 citation statement)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…iPSCs can be generated from somatic cells of T1D patients ( 100 , 101 ), and further differentiate into pancreatic β cells ( 19 , 102 ), cardiomyocytes ( 103 ), and macrophages ( 104 ). Studies have shown that T1D-iPSCs-derived β cells/insulin-producing cells/pancreatic progenitor cells express β cell markers (NKX6-1 and Pdx1) and have global gene expression patterns like β cells from control iPSCs ( 19 , 105 , 106 ).…”

Section: T1dmentioning

confidence: 99%

Research progress of autoimmune diseases based on induced pluripotent stem cells

Ren,

Jiang,

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Autoimmune diseases can damage specific or multiple organs and tissues, influence the quality of life, and even cause disability and death. A ‘disease in a dish’ can be developed based on patients-derived induced pluripotent stem cells (iPSCs) and iPSCs-derived disease-relevant cell types to provide a platform for pathogenesis research, phenotypical assays, cell therapy, and drug discovery. With rapid progress in molecular biology research methods including genome-sequencing technology, epigenetic analysis, ‘-omics’ analysis and organoid technology, large amount of data represents an opportunity to help in gaining an in-depth understanding of pathological mechanisms and developing novel therapeutic strategies for these diseases. This paper aimed to review the iPSCs-based research on phenotype confirmation, mechanism exploration, drug discovery, and cell therapy for autoimmune diseases, especially multiple sclerosis, inflammatory bowel disease, and type 1 diabetes using iPSCs and iPSCs-derived cells.

show abstract